Uniquely amongst vitamin K-dependent coagulation proteins, protein C interacts via its Gla domain both with a receptor, the endothelial cell protein C receptor (EPCR), and with phospholipids. We have studied naturally occurring and recombinant protein C Gla domain variants for soluble (s)EPCR binding, cell surface activation to activated protein C (APC) by the thrombin-thrombomodulin complex, and phospholipid dependent factor Va (FVa) inactivation by APC, to establish if these functions are concordant. Wild-type protein C binding to sEPCR was characterized with surface plasmon resonance to have an association rate constant of 5.23 · 10 5 m )1 AEs )1 , a dissociation rate constant of 7.61 · 10 )2 s )1 and equilibrium binding constant (K D ) of 147 nm. It was activated by thrombin over endothelial cells with a K m of 213 nm and once activated to APC, rapidly inactivated FVa. Each of these interactions was dramatically reduced for variants causing gross Gla domain misfolding (R-1L, R-1C, E16D and E26K). Recombinant variants Q32A, V34A and D35A had essentially normal functions. However, R9H and H10Q ⁄ S11G ⁄ S12N ⁄ D23S ⁄ Q32E ⁄ N33D ⁄ H44Y (QGNSEDY) variants had slightly reduced (< twofold) binding to sEPCR, arising from an increased rate of dissociation, and increased K m (358 nm for QGNSEDY) for endothelial cell surface activation by thrombin. Interestingly, these variants had greatly reduced (R9H) or greatly enhanced (QGNSEDY) ability to inactivate FVa. Therefore, protein C binding to sEPCR and phospholipids is broadly dependent on correct Gla domain folding, but can be selectively influenced by judicious mutation. [10, 11] . Cleavage at Arg506 occurs approximately 20-fold faster than cleavage at Arg306 [12] , and this step is greatly accelerated by the presence of anionic phospholipids [13] . The cleavage at Arg679 (the slowest of the three cleavage steps) is of uncertain functional significance, but may contribute to the inactivation of two naturally occurring FV variants, FV Cambridge and FV Hong Kong [14] . APC also activates proteaseactivated receptor 1 (PAR1) [15] , and has been shown to protect brain endothelial cells from p53-mediated apoptosis in an EPCR-dependent manner [16] . Cell surface full-length EPCR (residues 1-221, mature protein numbering) and truncated EPCR (soluble or sEPCR, residues 1-193) bind protein C and APC with equal affinity [17] [18] [19] . The interaction of protein C with EPCR ⁄ sEPCR is dependent upon Ca 2+ ions [3, 18] . The Gla domain of protein C, through which the interaction with EPCR takes place, is the source of this Ca 2+ dependence [20] . The Gla domain contains post-translationally c-carboxylated Glu residues and undergoes a large structural transition in the presence of physiological concentrations of Ca 2+ ions [21] [22] [23] . A critical step in the structural transition is the formation of the x-loop (approximately residues 1-11) [24, 25] . This endows protein C, and other vitamin K-dependent proteins, with the ability to bind anionic phospholipid surfaces [16, 26, 27] and is therefore crucial for its activity.
The crystal structures of recombinant sEPCR, and sEPCR in complex with the Gla domain of protein C, have recently been solved [25] . As predicted [18, [28] [29] [30] , the overall fold of sEPCR is similar to that of the CD1 ⁄ MHC class I family of proteins, consisting of a b-pleated sheet platform supporting two a-helices. A tightly bound phospholipid moiety was found to reside in the groove between the two a-helices of the EPCR. Although it does not seem to interact with protein C directly, the phospholipid moiety appears to be required for protein C binding to EPCR [25] . A small clustered patch of residues on the EPCR, which include residues on both a-helices, was found to interact with protein C [31] . These residues were positioned to interact with the Gla domain of protein C, specifically the x-loop.
Information on the functional consequences of residue substitution in the protein C Gla domain has come from two sources. Firstly, protein C deficiency is a known risk factor for venous thrombosis and the mutational analysis of this deficiency has identified causative amino acid substitutions [32] . Type II (functional) deficiency is associated with normal protein C antigen levels but reduced activity. Type II clotting deficiency is diagnosed when the amidolytic activity with respect to synthetic substrates is normal, but the anticoagulant activity is reduced. In the latest published update of the protein C deficiency database, of the 335 mutations (161 unique events) that have been identified in patients in association with protein C deficiency, at least 30 are associated with type II clotting deficiency and 14 of these are located in the Gla domain [32] . Secondly, more detailed structure-function relationships have been identified by in vitro mutagenesis and expression of recombinant protein C variants. Using this approach, loss-and gain-of-function variants have been characterized [33] [34] [35] [36] [37] [38] [39] .
Most investigations of the functional properties of protein C Gla domain variants have focused upon APC interaction with anionic phospholipids and the subsequent effect on FVa inactivation; that is the anticoagulant function of the enzyme. Before this anticoagulant function can be expressed, however, protein C must first be activated on the endothelial cell surface. Activation involves protein C interaction with EPCR and presentation of EPCR-bound protein C to the thrombin-thrombomodulin complex for proteolysis of its activation peptide. In this report, we examine how binding to EPCR is influenced by protein C Gla domain mutation, with particular reference to naturally occurring protein C Gla domain variants associated with type II clotting deficiency. We also provide the first evidence that the EPCR and membrane binding properties of protein C can be selectively influenced by specific mutation.
Results

Expression and characterization of recombinant EPCR
Recombinant wild-type sEPCR was prepared using the yeast Pichia pastoris expression system. In addition to binding protein C with expected affinity (see below), the wild-type sEPCR was also able to inhibit the anticoagulant activity of APC in a modified clotting assay, as described previously [ 1 40] . Using SDS ⁄ PAGE and Western blot analysis with the rat monoclonal RCR-2, sEPCR was found to be heterogeneous, probably due to N-linked glycosylation. Indeed, treatment of sEPCR with PNGase F resulted in increased mobility and the smeared bands resolved into a single defined band (data not shown). Variant forms of sEPCR were generated by site-directed mutagenesis (N30Q, L37A and E86A) and were expressed, concentrated and bufferexchanged using gel filtration. These mutants migrated with similar mobility to that of wild-type sEPCR on SDS ⁄ PAGE, except for variant N30Q that had slightly increased mobility attributed to the removal of a predicted carbohydrate side chain.
Expression and characterization of protein C Gla domain variants
Two natural protein C variants, R-1L and R-1C, were selected for study and the variant component isolated from plasma. Two other naturally occurring protein C variants, R9H and E26K, were expressed using HEK293 cells. Protein C variants with point mutations (E16D, Q32A, V34A and D35A) were also generated. Finally, a variant with multiple residue substitutions, H10Q ⁄ S11G ⁄ S12N ⁄ D23S ⁄ Q32E ⁄ N33D ⁄ H44Y (QGNSEDY), reported previously to exhibit enhanced anionic phospholipid affinity and increased anticoagulant activity [37] , was also studied. Recombinant variants were expressed at concentrations ranging between 0.9 and 7 lgAEmL )1 and migrated as closely spaced 62 kDa doublets under nonreducing conditions (data not shown), in accordance with previous reports [36, 37, 41, 42] . Expressed protein C was subsequently concentrated and partially ⁄ fully purified from conditioned medium by ion-exchange chromatography. To ensure that the catalytic site of each variant was functional, they were activated by the human protein C carrier, Protac 2 , and their amidolytic properties evaluated. The wild-type and variant preparations could all be fully activated by Protac and efficiently cleaved the chromogenic substrate S-2366, with K m and k cat parameters comparable to those for wild-type APC described in the literature [43] (data not shown).
Activation of protein C Gla domain variants on the surface of endothelial cells
To investigate the activation of protein C variants by the thrombin-thrombomodulin complex in the presence of EPCR, each variant was activated by thrombin over the surface of an endothelial cell line 3 , EA.hy926. The activation of recombinant wild-type protein C was characterized by a K m of 213 ± 42 nm ( Fig. 1 and Table 1 ), similar to the K m for plasma protein C activation (155 nm; data not shown) and similar to previously reported values [4] .
The activation of variants E16D and E26K by thrombin on EA.hy926 cells at concentrations up to 1 lm was barely detectable (Fig. 1A and Table 1 ). However, small amounts of protein C could be activated on the surface of endothelial cells at concentrations higher than 1 lm, suggesting some activation by the thrombin-thrombomodulin complex had taken place (data not shown).
The K m values for activation of variants R9H, Q32A, V34A, D35A and QGNSEDY on the cell surface were normal or slightly increased ( Fig. 1 and Table 1 ). Activation of QGNSEDY and R9H variants was also characterized by slight increases in the V max for this reaction, with the increase for QGNSEDY being approximately twofold (Fig. 1A, Table 1 ). To further investigate this, the activation of QGNSEDY by thrombin on the surface of cells expressing thrombomodulin alone was determined. Interestingly, over the surface of HEK293-TM cells, the K m for activation of wild-type protein C and QGNSEDY by thrombin were closely comparable (K m ¼ 666 ± 182 nm and 603 ± 112 nm, n ¼ 3), respectively, with no difference in V max . This indicated that the increased V max was dependent upon cell-surface EPCR.
Affinity of protein C Gla domain variants for sEPCR
Surface plasmon resonance (SPR) was used to analyse the binding kinetics of each protein C variant for sEP-CR. sEPCR has been previously reported to lose activity when bound directly to artificial surfaces [4] . Therefore, the anti-EPCR monoclonal antibody, RCR-2, was first immobilized onto the surface of a CM5 sensor chip, and sEPCR captured onto one of the two flow cells of the sensor chip. Table 2 ).
The K D for this variant was also increased to 16.3 ± 1.4 nm. These results demonstrate a slow off rate (k d ) for the interaction between wild-type sEPCR and RCR-2 and furthermore suggest that the epitope for RCR-2 on sEPCR is on the face of sEPCR opposite to its known binding site for protein C. The stability of immobilized RCR-2 as a capture ligand for sEPCR and protein C is illustrated in Fig. 2C . This shows initial binding of sEPCR to RCR-2 ( Fig. 2C ; panel 1), the addition of increasing concentrations of protein Cshowing association, dissociation and regeneration experiments -( Fig. 2C ; panel 2) and final regeneration of the RCR-2 immobilized chip by injection of 10 mm glycine ⁄ HCl ( Fig. 2C; panel 3 ).
The binding of protein C to sEPCR was initially characterized using wild-type and variant forms of sEP-CR. Human plasma protein C associated with RCR-2 immobilized wild-type sEPCR in a concentrationdependent manner (Fig. 3A) . The association and dissociation rate constants were 12. (Table 3) . Also, no detectable binding for variants E16D and E26K to sEPCR was observed at concentrations up to 200 nm (Table 3 ). Protein C variants R9H, Q32A, V34A, D35A, and QGNSEDY variants had readily detectable binding to sEPCR, but all exhibited slightly reduced affinities compared to recombinant wild-type protein C (Table 3) . Repeated analyses also suggested slightly faster dissociation rates (approximately twofold) for the R9H and QGNSEDY variants compared to recombinant wild-type protein C, which may have contributed to the increased K D values of 256 ± 96 and 216 ± 53 nm, respectively ( Table 3) .
Inactivation of FVa by APC Gla domain variants
The inactivation of FVa on phospholipids by APC is strongly dependent on APC binding to anionic phospholipids. Therefore, to indirectly assess APC variant affinity for phospholipids, FVa inactivation by each recombinant variant was determined. 
were derived from the SPR data using Biacore software (BIAEVALUATION 3.0). Data sets were fit to the 1 : 1 Langmuir model (see Experimental procedures). Rate constants are presented as the mean value of (n ¼ 2-4) independent experiments ± SD.
Wildtype ( . Dissociation of protein C from sEPCR was achieved by injection of HBS-EP buffer, containing 3 mM EDTA. 3, Injection of 10 mM glycine ⁄ HCl pH 2.5 regenerated the antibody surface by the complete removal of sEPCR from the CM5 chip surface. The data shown in the figure are representative sensograms for each set of experiments. 
Discussion
Vitamin K-dependent proteins interact through their characteristic Gla domains with phospholipid membrane surfaces. The Gla domains exhibit appreciable amino acid sequence similarity. When Ca 2+ is bound, the Gla domain folds into a conserved x-loop exposing surface-orientated hydrophobic residues that are proposed to make membrane contact [26] . The membrane binding properties of vitamin K-dependent proteins is facilitated by the presence of phosphatidylserine. Recent analysis of the prothrombin Gla domain complexed with lysophosphatidylserine identified interactions of the serine head group with bound Ca 2+ ions, Gla17 and Gla21. Extensive interactions were also detected between lysophosphatidylserine and residues of the x-loop, including Phe5, Leu6 and Gla7. Furthermore, the glycerophosphate backbone was shown to interact with a basic region of the Gla domain containing Lys3, Arg10 and Arg16 [27]. Consequently, a general model of Gla domain membrane contact has been proposed that involves both hydrophobic and ionic interactions. Such a model is compatible with experimental data showing the limited effects of targeted mutagenesis on Gla domain binding to membranes [33] .
Of the coagulation proteins, protein C is unique in binding EPCR with high affinity. This interaction is mediated by the protein C Gla domain. According to a recent crystal structure [25] , the majority of protein C residues contributing to the EPCR interaction are located on the x-loop. One direct pivotal contact was shown to be made between the Ca 2+ ions bound to the protein C Gla domain and the EPCR (Glu86 of EPCR). All remaining contacts (hydrogen bonds and ⁄ or hydrophobic interactions) were directly between residues of the protein C Gla domain (Phe4, Gla7, Leu8, Gla25 and Gla29) and EPCR (Leu82 ,   Table 3 . Interaction of protein C Gla domain variants with recombinant wildtype sEPCR. Affinity of protein C Gla domain variants for sEPCR was assessed using SPR. The association rate constants (k a ), dissociation rate constants (k d ) and equilibrium dissociation rate constants (K D ) were derived as described in Experimental procedures using the 1 : 1 binding with drifting baseline model. Association and dissociation rates and equilibrium binding constants are presented as the mean of three independent experiments ± standard deviation. Arg87, Gln150, Tyr154 and Thr157). Consequently, the structural features of protein C required for membrane and EPCR interactions appear to be partially shared.
In this study, the contributions of protein C Gla domain residues to both of these interactions, and their subsequent effect on anticoagulant activity, have been examined. Nine plasma ⁄ recombinant protein C variants were isolated or generated, and four of these were selected because they are known to have impaired anticoagulant activity. Each of the nine variants were characterized by activation over the surface of endothelial cells, their binding to recombinant sEPCR, and by their abilities to inactivate FVa in a phospholipiddependent manner. Two of the variants (R-1L and R-1C) were purified from the plasma of heterozygous carriers. These variants are incorrectly processed by the signal peptidase at their amino-terminal residues. Furthermore, a proportion of the R-1C variant is known to be present as heterodimers with a 1 -microglobulin [45] . Neither variant was able to bind to sEP-CR or be efficiently activated by thrombin over the endothelial cell surface. A further means of inhibition of the Ca 2+ -induced conformational change of the protein C Gla domain is the substitution of c-carboxylated Glu residues. Two such substitutions arise in the naturally occurring variant E26K [46, 47] and the engineered conservative substitution variant E16D. They too are shown here to be unable to bind sEPCR (Table 3) , have negligible activation over the surface of endothelial cells by the thrombin-thrombomodulin complex (Table 1) , and to have grossly impaired abilities to inactivate FVa once activated to APC (Fig. 4A) .
As the natural and recombinant variants described above have such abnormal binding and activation properties, it was of interest to study other protein C recombinant variants in the protein C Gla domain that might be predicted to perturbate, but not fully disrupt, Gla domain folding and functions. Three potentially dysfunctional variants with substitutions Q32A, V34A and D35A were chosen for investigation because of a preliminary abstract report that suggested the binding site for the EPCR on protein C was located between residues 25 and 40 [48] . This report was based upon the observation that a chimeric molecule with residues 1-22 of prothrombin and 22-45 of protein C bound EPCR, whereas a protein C chimera with residues 1-45 of prothrombin did not. We therefore selected three residues on protein C that differed from the homologous prothrombin sequence [49] and generated variants containing an alanine residue at each of these positions. In the event, the interactions of these variants with sEPCR were essentially normal (Table 3) , as was their activation over the endothelial cell surface (Table 1) and their ability to inactivate FVa once activated to APC (Fig. 4B) .
The R9H variant, another example of a Gla domain residue substitution causing a type II deficiency phenotype [50] , displayed only a small reduction in affinity for sEPCR and a similar K m for endothelial cell activation by thrombin to that of wild-type protein C (Tables 1 and 3 ). In contrast, the ability of the R9H APC variant to fully inactivate FVa was markedly compromised (Fig. 4) suggestive of an impaired interaction with anionic phospholipids. The R9H substitution may therefore selectively perturbate protein C Gla domain function by reducing protein C Gla domain affinity for phospholipids without substantially affecting interaction with EPCR. The homologous residue in the bovine prothrombin Gla domain, Arg10 is discussed above. Our results suggest that Arg9 may form part of a similar basic region on the protein C Gla domain surface for contact with phosphatidylserine, and thereby contribute importantly to the protein C ⁄ APC-phospholipid interaction.
Further evidence for selective modulation of protein C Gla function is provided from results of the protein C variant QGNSEDY. This variant exhibited near-normal sEPCR binding (a K D value of 216 nm compared to 147 nm for wild-type protein C; Table 3 ), which appears to be caused by an increased k d . The K m and V max for activation of this variant on the endothelial cell surface by the thrombin-thrombomodulin complex were slightly increased (Table 1 and Fig. 1 ). In contrast, the ability of QGNSEDY to inactivate FVa in a phospholipid-dependent manner was markedly enhanced (Fig. 4A) , as has been reported previously [37] . Because of the composite nature of the QGNSEDY variant, it is currently uncertain how its Gla domain has been selectively altered to enhance phospholipid binding.
The results of this study highlight for the first time the importance of natural protein C Gla domain mutations in impairing protein C binding to EPCR and its endothelial cell surface activation by the thrombinthrombomodulin complex. Carriers of certain protein C Gla domain mutations are known to be at increased risk of thrombosis. It is highly plausible that impaired cell surface protein C activation could contribute to that risk. Protein C variants with gross misfolding of the Gla domain will have impaired cell surface activation that will in part be determined by a reduced interaction with EPCR. Patients with heterozygous R-1L or R-1C mutations, in particular, have been reported to present with a severe thrombotic manifestation. In such an instance, a deficiency of anticoagulant activity will arise from reduced APC activity against FVa due to loss of phospholipid affinity, but potentially also from an impaired rate of protein C activation, an inevitable by-product of deficient EPCR binding.
Recombinant APC is one of the few novel therapies to be used successfully in the treatment of sepsis [51] . Its ability to reduce mortality appears due in part to EPCR-bound APC proteolysis of PAR1 on the surface of endothelial cells [15] . PAR1 cleavage by APC has been shown to mediate signal transduction pathways and contribute to APC antiapoptotic and neuroprotective activities [16, 52] . This nonanticoagulant activity is entirely reliant on the APC-EPCR interaction. Selective perturbation of protein C ⁄ APC Gla domain functions therefore represents a potential means by which the anticoagulant and nonanticoagulant functions of APC can be altered for improved therapeutic intervention in the future.
Experimental procedures
Expression and purification of sEPCR sEPCR was expressed in Pichia pastoris strain X-33 using the EasySelect Pichia expression kit (Invitrogen, Paisley, UK) broadly as described [53] . SEPCR variants were generated using the QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA).
Purification of variant protein C from plasma of heterozygous carriers
The purification of variant protein C from the plasma of patients who were heterozygous for the mutations R-1L and R-1C has been described previously [45, 54] . Briefly, the method utilized two immunoaffinity columns directed against protein C. The first column resulted in efficient purification of protein C from other plasma components, whereas the second separated normal from variant protein C. The characterization of these APC variants has also been reported previously [45, 54] and consequently details of the purification and characterization will not be replicated here. The activities of these variants were compared to human plasma protein C from Enzyme Research Laboratories (ERL, South Bend, IN, USA).
Vector construction and expression of recombinant protein C
The full-length protein C cDNA was cloned into the vector pRc ⁄ CMV (Invitrogen, Paisley, UK) 4 to generate wild-type protein C. Site-directed mutagenesis was performed by the Quikchange mutagenesis kit (Stratagene, La Jolla, CA, USA) 5 to generate protein C variants. The oligonucleotide primers used to generate the protein C variant constructs R9H, E16D, E26K, Q32A, V34A and D35A are available upon request. Preparation of the H10Q ⁄ S11G ⁄ S12N ⁄ D23S ⁄ Q32E ⁄ N33D ⁄ H44Y construct has been described previously [37] . The expression of recombinant protein C using picked colonies of stably transfected HEK293 cells (European Collection of Cell Cultures, Wiltshire, UK) has been described in detail elsewhere [36, 37] . Serum-free conditioned medium containing protein C was dialysed overnight against 20 mm Tris ⁄ HCl (pH 7.4), 150 mm NaCl. Protein C was concentrated and partially or fully purified by ion-exchange chromatography in 20 mm Tris ⁄ HCl, 150 mm NaCl (pH 7.4), using a Q Sepharose Fast Flow column (Amersham Biosciences, Little Chalfont, UK), with either a single step elution to 1 m NaCl or elution with 3 mm CaCl 2 [37] . Purified fractions were dialysed overnight against Hanks Balanced Salt Solution (HBSS) before use. Expressed protein C has been shown to have normal c-carboxylation [37] .
Determination of protein C concentration
Protein C concentrations were determined either by absorbance at 280 nm or by an 'in-house' ELISA. For the latter, the method was similar to that previously described for the determination of protein S concentration [55] . The only modifications were the antibodies used. The capture antibody was the monoclonal antibody HC-2 (directed towards the heavy chain of protein C) (Sigma-Aldrich, Poole, UK) and the detection antibody was a horseradish peroxidase (HRP)-conjugated polyclonal anti-protein C (Dako, Ely, UK). SPR was used to confirm that the affinity of each protein C variant for the capture antibody was identical, and unaffected by Gla domain mutation. Standards (0.2-7.8 lgAEmL )1 ) for the ELISA were prepared using purified plasma protein C.
SDS ⁄ PAGE and Western blotting
SDS ⁄ PAGE and Western blotting were performed using standard techniques. Briefly, for Western blot analysis, protein C or sEPCR were loaded and separated by SDS ⁄ PAGE in a 4-20% (w ⁄ v) polyacrylamide Tris ⁄ HCl gel (Bio-Rad, Hemel Hempstead, UK) 6 under nonreducing or reducing conditions. Proteins in the gel were stained with GelCODE Blue stain reagent (Pierce, Rockford, IL, USA). Proteins transferred to Hybond-ECL (Amersham Biosciences) were detected using either an HRP-conjugated polyclonal anti-protein C or the anti-EPCR monoclonal antibody RCR-2 followed by an HRP-conjugated goat anti-(rat IgG) Ig (both from Dako).
Determination of catalytic efficiency of APC variants
Protein C was activated with Protac (Immuno, Heidelberg, Germany) according to the method of Zhang and Castellino [56] . Protein C at 5 lgAEmL )1 was incubated in 50 mm
Tris ⁄ HCl (pH 7.4), 100 mm NaCl and 0.25 U Protac in a total volume of 1 mL for 1 h at 37°C then 16 h at 4°C. Steady-state substrate hydrolysis by each APC variant was measured using an adapted method [57] . Essentially, 2 nm of each APC variant was incubated with a range of concentrations of chromogenic substrate (S-2366; Chromogenix, Milan, Italy) in 100 mm NaCl, 20 mm Tris ⁄ HCl (TBS, pH 7.5) containing 2.5 mm CaCl 2 , 0.1 mgAEmL )1 BSA and 0.1% (v ⁄ v) polyethylene glycol (PEG 8000). The rate of S-2366 hydrolysis was measured at 405 nm at room temperature using an iEMS plate reader MF (Labsystems, Basingstoke, UK). Curve fitting using the MichaelisMenten equation was performed using enzfitter software (Biosoft, Cambridge, UK). The K m and k cat values were derived from this equation.
Activation of protein c on endothelial cells and HEK293-TM cells
EA.hy926 cells (the kind gift of C.-J. Edgell, University of North Carolina, Chapel Hill, NC, USA) were used as they express both EPCR [3, 5] and thrombomodulin [58] . The method of protein C activation was a modification of that described by Suzuki et al. [59] . Cells were grown to confluence in 96-well plates and were washed using HBSS supplemented with 1% (w ⁄ v) BSA, 3 mm CaCl 2 , 0.6 mm MgCl 2 and 0.1% (w ⁄ v) NaN 3 (cHBSS-NaN 3 ). Serial dilutions of protein C (12.5-1000 nm) were prepared in cHBSS-NaN 3 (ensuring a final concentration of 3 mm CaCl 2 and 0.6 mm MgCl 2 ) and added to the wells. Activation was initiated by the addition of purified human thrombin (ERL) (13.5 nm final concentration) to each well and was allowed to proceed for 30 min at 37°C with gentle shaking. The reaction was terminated by the addition of hirudin (Sigma) (135 nm final concentration). Fifty microlitres of the resulting supernatant was incubated with 50 lL of 2 mm S-2236 chromogenic substrate and the initial rate of increase in absorbance at 405 nm was determined using an iEMS plate reader MF. Generated APC was estimated using a standard curve of purified APC. Curve fitting of the data to the Michaelis-Menten equation was performed using enzfitter software.
For activation of protein C on cells expressing thrombomodulin only, a similar assay was used, except that HEK293 cells stably transfected with full-length thrombomodulin (HEK293-TM) were used. Briefly, HEK293-TM cells were plated on a poly(l-lysine) (Sigma) coated 96-well plate, and grown to confluence over a 24-h period. The cells were washed gently, and protein C (25-3000 nm) in cHBSS-NaN 3 was added to the wells. Thrombin (13.5 nm final concentration) was added to each well, and the plate was then incubated for 30 min at 37°C with gentle shaking. The reaction was stopped with hirudin (135 nm final concentration). Generation of APC was assessed using the chromogenic substrate S-2366 as above.
Assessment of protein C-sEPCR interaction by surface plasmon resonance (SPR)
All binding experiments were assessed by SPR using a dual flowcell BIAcoreÒ X biosensor system (BIAcore, AB, Uppsala, Sweden). To determine the concentration of sEPCR, an anti-EPCR monoclonal antibody (RCR-2) was covalently immobilized on a carboxymethylated dextran (CM5) sensor chip (BIAcore) using amine coupling chemistry, according to the manufacturer's instructions. A single time point on the association phase of wild-type sEPCR binding in triplicate was used to generate a calibration curve for sEPCR binding, the linear range of which was between 12.5 and 200 ngAEmL )1 .
To characterize sEPCR binding to RCR-2, immobilization was performed by injecting 200 ng RCR-2 across the sensor chip surface at a flow rate of 5 lLAEmin To investigate protein C binding to sEPCR, protein C and concentrated sEPCR samples were buffer-exchanged into HBS-P with 3 mm CaCl 2, 0.6 mm MgCl 2 by gel filtration. RCR-2 (300 ng) was injected for 6 min across both flow cells of a CM5 chip, generating a response of 3000-6000 RU. sEPCR in HBS-P, containing 3 mm CaCl 2 and 0.6 mm MgCl 2 , was injected and equilibrated at 10 lLAEmin 
Kinetic analysis of protein C binding to sEPCR
Data analysis was performed using the biaevaluation software 3.0 (BIAcore). The association and dissociation phases of all sensograms were fitted globally. Kinetics of wild-type and variant forms of sEPCR binding to RCR-2 were determined using a 1 : 1 Langmuir binding model. Protein C binding to sEPCR was fitted to a 1 : 1 baseline drift linear model.
Phospholipid vesicle preparation
A phospholipid mixture containing dioleoyl-phosphatidylcholine and dioleoyl-phosphatidylserine (90 : 10, v ⁄ v) in chloroform (Avanti Polar Lipids Inc, Alabaster, AL, USA) was prepared, and the chloroform evaporated under nitrogen vapour. The phospholipids were resuspended in ice-cold sterile water then mixed vigorously for 1 h with shaking at 4°C. Unilamellar phospholipid vesicles were prepared by extrusion. The resuspended vesicles were passed 19 times through a 0.1 lm membrane, then a further 19 times through a 0.03 lm membrane using an Avanti Mini-Extruder (Avanti Polar Lipids Inc).
Determination of APC-mediated factor Va inactivation
To determine FVa degradation by APC, 0.08 nm APC was incubated with 75 lm of the above phospholipid vesicles and 4 nm FVa (Haematologic Technologies Inc, VT, USA) in 40 mm Tris ⁄ HCl, 140 mm NaCl, 3 mm CaCl 2 and 0.3% (w ⁄ v) BSA (0.02 nm APC, 19 lm phospholipids and 1 nm FVa; final concentration). The mixture was incubated at 37°C, and 2 lL aliquots removed and added to a prothrombinase mixture, consisting of 75 lm phospholipids (phosphatidylcholine and phosphatidylserine; 90 : 10, v ⁄ v), 3 nm factor Xa and 1.5 lm prothrombin (Haematologic Technologies Inc) (25 lm phospholipids, 1 nm factor Xa and 0.5 lm prothrombin; final concentration) at defined time points between 0 and 20 min. Each reaction was stopped after three minutes using 3 lL ice-cold 0.5 m EDTA. One-hundred microlitres of the reaction mixture was then removed and incubated with 50 lL of chromogenic substrate S-2238 to assess thrombin generation, as the rate of thrombin generation was proportional to FVa activity. Calculation of kinetic rate constants for cleavage at Arg506 and Arg306 of FVa by APC was achieved using a model described previously for this purpose [12] . CT (1997) The interaction between the endothelial cell protein C receptor and protein C is dictated by the gamma-carboxyglutamic acid domain of protein C. 
